Extracting therapeutic antibodies from biological systems requires stringent purification processes. To reduce costs and accelerate development, novel strategies are essential ...

The new DeltaV MES Recipe Importer Tool automates batch record creation for workflow execution, reducing timelines from ...

The industry has learned how the ball bounces—now it must decide where to play next.  | While 2025 was dedicated to “understanding a little bit more about the rules of this game that we’re playing,” ...

Saudi Arabia-owned energy contractor Kent is targeting new opportunities in the Middle East and beyond after rounding off 2025 with a record backlog of projects. In an exclusive interview, Kent’s ...

While policy shifts and leadership shakeups at institutions like the Food and Drug Administration dominated headlines in 2025, drugmakers would do well to sift through the noise and remain focused on ...

Ultragenyx shares plunge as bone disease drug fails to reduce fracture rate Ultragenyx Pharmaceutical said on Monday that late-stage studies showed its drug for a type of genetic bone disease failed ...

ArriVent BioPharma is rated a Strong Buy, driven by Firmonertinib's near-term clinical catalysts and significant de-risking from Shanghai Allist Pharmaceuticals commercialization. Firmonertinib has ...

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

INDIANAPOLIS (WISH) — INCOG BioPharma Services announced Tuesday it will invest approximately $200 million in its manufacturing facility in Fishers to expand its injectable drug product manufacturing ...

Adam Feuerstein, a senior writer and biotech columnist, is the author of Adam’s Biotech Scorecard, a subscriber-only newsletter about the crossroads of drug development, business, Wall Street, and ...

Cormorant Asset Management is raising money for a new blank-check company. The biopharma and life sciences firm known for its hedge fund has filed plans to raise $125 million for Helix Acquisition ...